Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
Johnson and Johnson
Cantor Fitzgerald
Harvard Business School
Cipla
Deloitte
Julphar
QuintilesIMS

Generated: April 25, 2018

DrugPatentWatch Database Preview

ACCOLATE Drug Profile

« Back to Dashboard

When do Accolate patents expire, and what generic alternatives are available?

Accolate is a drug marketed by Par Pharm Inc and is included in one NDA.

The generic ingredient in ACCOLATE is zafirlukast. There are four drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the zafirlukast profile page.
Drug patent expirations by year for ACCOLATE
Synonyms for ACCOLATE
[3-?[[2-?METHOXY-?4-?[[[(2-?METHYLPHENYL)SULFONYL]AMINO]CARBONYL]PHENYL]METHYL]-?1-?METHYL-?1H-?INDOL-?5-?YL]-?CARBAMIC ACID,? CYCLOPENTYL ESTER
107753-78-6
32256-EP2270008A1
32256-EP2280006A1
32256-EP2281813A1
32256-EP2281815A1
32256-EP2281819A1
32256-EP2284166A1
32256-EP2292617A1
32256-EP2292619A1
32256-EP2295409A1
32256-EP2298415A1
32256-EP2301933A1
32256-EP2305640A2
32256-EP2305659A1
32256-EP2308562A2
32256-EP2311818A1
32256-EP2311827A1
4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide
4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide
4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide
4CH-018070
753Z786
A801752
AB0012638
AB00639922_09
AB00639922-06
AB00639922-08
AB2000178
AC-9018
AC1L1KZB
Accolate (TN)
Accolate, Accoleit, Vanticon, Zafirlukast
Accolate;Accoleit;Vanticon
Accoleit
Accoleit (TN)
ACMC-209wlw
Aeronix
AK-72849
AKOS005577888
AN-7458
ANW-46530
AS-12943
AstraZeneca brand of zafirlukast
BC201090
BDBM50009073
BG0591
BG0649
BIDD:GT0267
Bio-0152
BR-72849
BRD-K71289571-001-06-4
C-23263
C07206
C31H33N3O6S
Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester
CAS-107753-78-6
CC-35662
cc-92
CCG-101025
CHEBI:10100
CHEMBL3560623
CHEMBL603
CPD000466316
CS-2167
CTK4A5698
cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate
Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate
cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate
Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate
cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate
cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methyl-1H-indol-5-yl]carbamate
cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methylindol-5-yl]carbamate
cyclopentyl N-[3-[[2-methoxy-4-(o-tolylsulfonylcarbamoyl)phenyl]methyl]-1-methyl-indol-5-yl]carbamate
cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-indol-5-yl]carbamate
cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate
Cyclopentyl N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamate
cyclopentyl N-{3-[(2-methoxy-4-{[(2-methylbenzene)sulfonyl]carbamoyl}phenyl)methyl]-1-methyl-1H-indol-5-yl}carbamate
D00411
D05DVP
DB00549
DR003304
DSSTox_CID_3746
DSSTox_GSID_23746
DSSTox_RID_77181
DTXSID5023746
FT-0601575
GP6218
GTPL3322
HE213448
HMS2051F12
HMS2089J10
HMS3393F12
HMS3650A04
HMS3655E13
HY-17492
I06-0398
ICI 204,219
ICI 204219
ICI-204,219
ICI-204219
KS-00001D9L
L001011
LS-50025
MCULE-2053856450
Menarini brand of zafirlukast
MFCD00864775
MLS000759421
MLS000759421-02
MLS001424064
MLS006011771
MolPort-003-850-873
N-[3-[[2-methoxy-4-[[(2-methylphenyl)sulfonylamino]-oxomethyl]phenyl]methyl]-1-methyl-5-indolyl]carbamic acid cyclopentyl ester
N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic Acid Cyclopentyl Ester
NC00275
NCGC00164547-01
NCGC00164547-02
NCGC00164547-03
NCGC00164547-04
NCGC00164547-05
NCGC00164547-06
Novartis brand of zafirlukast
Olmoran
PubChem18223
Q-201940
Respix
RTR-001857
s1633
SAM001246577
SC-45160
SCHEMBL4175
SMR000466316
SR-01000759386
SR-01000759386-9
ST2406760
STK646780
Tox21_112176
Tox21_112176_1
TR-001857
UNII-XZ629S5L50
Vanticon
Vanticon (TN)
XZ629S5L50
YEEZWCHGZNKEEK-UHFFFAOYSA-N
Z1551429730
zafirlukast
Zafirlukast (Accolate)
Zafirlukast (JAN/USAN/INN)
Zafirlukast [USAN:BAN:INN]
Zafirlukast [USAN:INN:BAN]
Zafirlukast, >=98% (HPLC)
Zafirlukast(Accolate)
Zafirst
Zeneca brand of zafirkulast
ZINC896717

US Patents and Regulatory Information for ACCOLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ACCOLATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ACCOLATE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 10 mg and 20 mg ➤ Subscribe 2008-02-29

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Merck
Moodys
Accenture
Covington
US Department of Justice
Citi
Queensland Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.